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Endoglin is a transmembrane glycoprotein 633 residues in length
expressed at the surface of endothelial cells as a disulphide-linked
homodimer; the specific cysteine residues involved in endoglin
dimerization are unknown. Mutations in the coding region of the
endoglin gene are responsible for hereditary haemorrhagic tel-
angiectasia type 1 (HHT1), a dominantly inherited vascular
disorder. Many of these mutations, if translated, would lead to
truncated forms of the protein. It is therefore of interest to assess
the protein expression of different truncated forms of endoglin.
Infections in itro or in io with recombinant vaccinia virus, as
well as transient transfections with expression vectors, were used
to express normal and truncated forms of endoglin. Truncated
mutants could be classified into three different groups: (1) those
that did not produce stable transcripts ; (2) those that produced
stable transcripts but did not secrete the protein; and (3) those
that secreted a soluble dimeric protein. This is the first time that
INTRODUCTION
The gene encoding endoglin maps to chromosome 9q33–34 and
has been identified as the target for the dominant vascular
disorder known as hereditary haemorrhagic telangiectasia type 1
(HHT1) [1,2]. HHT is a highly penetrant autosomal dominant
vascular dysplasia associated with frequent epistaxis, gastro-
intestinal bleeding, telangiectases and arteriovenous mal-
formations in brain, lung and liver [3,4]. Endoglin (CD105) is a
180 kDa homodimeric membrane glycoprotein strongly ex-
pressed by human endothelial cells [5] ; it is also present in
syncytiotrophoblasts of full-term placenta [6], stromal cells [7,8]
and certain haemopoietic cells [9–12]. Two different isoforms, L-
endoglin and S-endoglin, differing in the amino acid compositions
of their cytoplasmic tails, have been characterized [13,14].
Endoglin binds transforming growth factor b (TGF)-b1 and
TGF-b3 with high affinity (K
d
fl 50 pM) in human endothelial
cells [15] and forms heteromeric associations with the TGF-b
signalling receptors types I and II [11,16] ; overexpression of
endoglin is able to modulate cellular responses to TGF-b [17].
The identification of the gene encoding Alk-1, a type I TGF-b
receptor, as the second locus of HHT [18] suggests the in-
volvement of the TGF-b system in the pathogenesis of this
disease. Nevertheless the molecular mechanisms by which endo-
glin gene mutations trigger the disease remain to be unveiled. So
far, more than two dozen mutations have been reported, showing
a clustering of premature termination mutations in various exons
coding for the extracellular domain of the protein [2,19–23]. If
translated, these mutant alleles would produce a soluble protein.
However, an analysis of a limited number of mutant proteins has
revealed instability or intracellular degradation, in agreement
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a recombinant truncated form of endoglin has been found to be
expressed in a soluble form. Because a chimaeric construct
encoding the N-terminal sequence of platelet}endothelial cell
adhesion molecule (PECAM-1) antigen fused to residues
Ile#)"–Ala’&) of endoglin also yielded a dimeric surface protein,
these results suggest that cysteine residues contained within the
fragment Cys$$!–Cys%"# are involved in disulphide bond for-
mation. Infection with vaccinia recombinants encoding an HHT1
mutation did not affect the expression of the normal endoglin,
and did not reveal an association of the recombinant soluble
form with the transmembrane endoglin, supporting a haplo-
insufficiency model for HHT1.
Key words: endothelial cells, hereditary haemorrhagic telangi-
ectasia 1, transforming growth factor-b, vaccinia virus.
with the 50% decrease in endoglin expression at the surface of
endothelial cells and activated monocytes from HHT1 patients
[21]. A haploinsufficiency model has therefore been proposed
that postulates that endoglin mutations lead to non-functional
alleles [21,22]. This model was later confirmed by the finding of
mis-sense mutations that disrupt the start codon of the gene [23].
Here we have assessed whether all truncated forms of endoglin
behave similarly. We have made several cDNA constructs
corresponding to truncated forms of endoglin and analysed their
expression and possible interference with the normal allele by
using transient transfections and infections with vaccinia virus.
MATERIALS AND METHODS
Antibodies
Mouse monoclonal antibodies (mAbs) 44G4 [anti-(human endo-
glin)] and HC1}6 [anti-(platelet}endothelial cell adhesion mol-
ecule) (anti-PECAM-1)] have been described previously [5,24].
Mouse mAb SN6h [12], recognizing an epitope within the
fragment Glu#’–Gly#$!, and mAb CLE4, specific for the fragment
Gly$$"–Gly&)’ of human endoglin [25], were obtained from the
endothelial panel of the Sixth International Workshop on Human
Leucocyte Differentiation Antigens. Mouse mAb 1H831, against
vaccinia haemagglutinin, was kindly provided by Dr. H. Shida
(Institute for Virus Research, Kyoto University, Kyoto, Japan).
Mouse mAb NIH31-2 [anti-(human PECAM-1)] was obtained
from the CD31 panel of the Fifth International Workshop on
Human Leucocyte Differentiation Antigens. mAb NIH31-2
recognizes an epitope within the IgG domains 1–2, whereas mAb
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HC1}6 recognizes an epitope within the IgG domains 3–6 of the
human PECAM-1 antigen [26]. Rat mAb MJ7}18 [anti-(mouse
endoglin)] [27] was a gift from Dr. E. Butcher (Stanford
University, Palo Alto, CA, U.S.A.). Mouse mAb P4A4, recog-
nizing an epitope within the fragment Tyr#((–Gly$$" of human
endoglin [25], was kindly provided by Dr. E. A. Wayner (Fred
Hutchison Cancer Research Center, Seattle, WA, U.S.A.). Rab-
bit polyclonal antibody BN against endoglin was obtained by the
immunization of rabbits with recombinant vaccinia virus (VV)-
EndoL as described below.
Plasmids
The pCEXV-EndoL vector containing the human L-endoglin
isoform driven by the SV40 promoter [14] was used to derive the
following truncated endoglin constructs. pCEXV-Endo*276:
pCEXV-EndoL was double-digested with BglII and MluI ; the
intervening segment was discarded, and annealed oligonucleo-
tides (5«-GATCTGGACCACTGGAGAATAGA-3« and 5«-CG-
CGTCTATTCTCCAGTGGTCCA-3«) encoding a stop codon
were inserted; the resulting construct encoded residues
Met"–Asp#(’ of endoglin and corresponded to an HHT1 mutation
[2]. pCEXV-Endo*437: pCEXV-EndoL was double-digested
with SacI and MluI ; the intervening segment was discarded, and
annealed oligonucleotides (5«-CATCACCACAGCGGTGAA-3«
and 5«-CGCGTTCACCGCTGTGGTGATGAGCT-3«) encod-
ing a stop codon were inserted; the resulting construct encoded
residues Met"–Arg%$( of endoglin. pCEXV-Endo*431: pCEXV-
EndoL was double-digested with SacI and MluI ; the intervening
segment was discarded, and the resulting plasmid was made
blunt-ended and religated. The resulting construct encoded
residues Met"–Ser%$" of endoglin plus the extension RVST-
PGPHSEHAGPLHPPGGAQ. pCEXV-Endo*437 and pCEXV-
Endo*431 were designed to truncate endoglin at the putative
protease cleavage sequence RKK at position 437, coinciding
with the boundary between exons 9 and 10. pCEXV-Endo*614:
pCEXV-EndoL was digested with MluI and made blunt-ended;
stop-linkers (5«-AATATTAGTTAGTTAG-3«) (Sigma) were
inserted; the resulting construct lacked the cytoplasmic domain
of endoglin and encoded residues Met"–Tyr’"%. A pcDNA}NEO
plasmid encoding a soluble form of human PECAM-1
(Met"–Lys’!") was generously provided by Dr. Peter J. Newman
(Milwaukee, WI, U.S.A.). pCEXV-PECAM-1}Endo was gene-
rated by inserting the 0.8 kb BamHI fragment of PECAM-1
cDNA into BglII-digested pCEXV-EndoL. The resulting plasmid
was digested with XbaI, made blunt, digested with HindIII to
remove the intervening sequence, and ligated with the 0.5 kb
EcoRI}HindIII fragment of the pCEXV vector previously made
blunt at the EcoRI site. The pCEXV-PECAM-1}Endo construct
encoded residues Met"–Ile#"% of PECAM-1 (including the leader
sequence and the first two IgG domains) fused to residues
Phe#)#–Ala’&) of endoglin (including part of exon 7 and exons
8–14). The correct orientation and sequence were verified in each
construct.
Construction of recombinant vaccinia virus
Culturing of the Western reserve strain vaccinia virus and
isolation of recombinant virus was performed as described [28].
Basically, plasmids pCEXV-EndoL, pCEXV-EndoS, containing
the L-endoglin or S-endoglin isoforms [14], pCEXV-Endo*276
and pCEXV-Endo*431 were digested with EcoRI; the result-
ing fragments were incubated with DNA polymerase I (Klenow
fragment) and inserted into the SmaI site of vaccinia virus
plasmid pSC11. The resulting plasmid is a vector that co-
expresses the endoglin gene or its mutants inserted downstream
of the vaccinia 7.5 kDa protein promoter, together with the
Escherichia coli b-galactosidase gene under the control of the
vaccinia 11 kDa protein late promoter ; both genes are flanked by
viral thymidine kinase sequences. Therefore, after homologous
recombination, both genes were inserted into the thymidine
kinase locus of the vaccinia virus genome. Control recombinant
TK− vaccinia virus (VV-TK−) was constructed as described for
the other recombinant viruses, by using the pSC11 plasmid.
Cell lines and transfections





blasts) and COS-7 cells were maintained in Dulbecco’s modified
Eagle’s medium supplemented with 10% (v}v) fetal calf serum
(FCS), 2 mM l-glutamine, penicillin (100 i.u.}ml) and strep-
tomycin (100 lg}ml) under 5% CO
#
at 37 °C. Mouse fibroblasts
NCTC929 were cultured in RPMI medium containing the same
supplements as above. Human umbilical vein endothelial cells
were isolated from cannulated vessels incubated in the presence
of collagenase for 20 min at 37 °C. Detached cells were plated in
gelatin-coated flasks and grown in RPMI 1640 supplemented
with 15% (v}v) FCS, 2 mM l-glutamine, penicillin (100 i.u.}ml)
and streptomycin (100 lg}ml), 5% (w}v) heparin and 50 lg of
epidermal growth factor.
Rat myoblast stable transfectants were generated by co-
transfecting pCEXV-EndoL and psV2neo at a 10:1 ratio.
Plasmid DNA (10 lg) was mixed with 20 lg of Lipofectin (Gibco
BRL) in serum-free medium in accordance with the protocol
provided by the manufacturer. Positive clones were selected in
the presence of the antibiotic G418 at 400 lg}ml. For transient
transfections, COS-7 cells were incubated with 5 lg of total
plasmid DNA mixed with 10 lg of Lipofectin as described
above.
Immunization of mice and rabbits
Groups of 6-week-old female Balb}c mice were injected intra-
peritonally with 10( plaque-forming units of VV-Endo-L, VV-
Endo*276, VV-Endo*431 or VV-TK− in PBS, and 2 weeks later
a booster injection of 5‹10) plaque-forming units was given.
After 2weeks, serawere collected and analysed byflow cytometry.
New Zealand rabbits (2.5 kg) were immunized with 10* plaque-
forming units of either VV-Endo-L or VV-TK− in PBS. The
immunization was repeated twice with a 4-week interval ; 2 weeks
after the last injection, sera were collected and analysed by
Western blotting.
Flow cytometry
Uninfected or vaccinia-infected [multiplicity of infection (m.o.i.)
1] cells were incubated with the indicated mAb or polyclonal
antiserum (dilution 1:1.000) for 30 min at 4 °C. After two
washes with PBS, FITC-labelled F(ab«)
#
rabbit anti-mouse Ig or
pig anti-rabbit Ig (Dakopatts) was added and incubation pro-
ceeded for an additional period of 30 min at 4 °C. Finally, cells
were washed twice with PBS and their fluorescence was estimated
with an EPICS-CS counter (Coulter Cientı!fica, Mo! stoles, Spain),
with the use of logarithmic amplifiers.
Western blot analysis
Uninfected or vaccinia-infected (m.o.i. 1) cells were cultured at a
density of 5‹10& cells}ml, collected by centrifugation, lysed and
extracts corresponding to 2‹10’ cells were subjected to SDS}
PAGE [7.5% or 10% (w}v) gels] under non-reducing conditions.
The supernatants of VV-Endo*276, VV-Endo*431 or VV-TK−
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infected cells (1.5 ml per 5‹10’ cells) were concentrated with a
Centricon-10 concentrator (Amicon, Beverly, MA, U.S.A.) to a
final volume of 100 ll ; 30 ll of the concentrate was subjected to
SDS}PAGE [7.5% (w}v) gels] under non-reducing conditions.
Proteins were electrophoretically transferred to nitrocellulose
membranes (Millipore Corp., Bedford, MA, U.S.A.). Filters
were blocked with PBS containing 5% (w}v) milk powder for
1 h. Specific immunodetection was performed by incubation with
mAb 44G4, mAb SN6h or with the rabbit polyclonal antiserum
BN(anti-endoglin) overnight, followedby peroxidase-conjugated
rabbit anti-mouse Ig or peroxidase-conjugated goat anti-rabbit
Ig at room temperature. The presence of endoglin was revealed
by using an enhanced chemiluminescence assay (ECL2 detection
kit ; Amersham Ibe! rica, Madrid, Spain).
Detection of inter-species endoglin heterodimers was per-
formed by immunoprecipitation followed by a Western blot
analysis. In brief, mouse fibroblasts were infected with VV-Endo-
L, lysed and subjected to immunoprecipitation with mAb P4A4
[anti-(human endoglin)] or mAb MJ7}18 [anti-(mouse endoglin)]
with Protein G–Sepharose (Pharmacia Biotech, Barcelona,
Spain). Immunoprecipitates were subjected to SDS}PAGE under
reducing conditions, transferred to nitrocellulose membranes
and incubated with the mAb MJ7}18 as described above. In this
case, a peroxidase-conjugated rabbit anti-rat Ig was used to
reveal the presence of mouse endoglin.
Metabolic labelling
Transiently transfected COS-7 cells were preincubated for 30 min
at 37 °C in methionine}cysteine-free RPMI medium containing
1% (v}v) FCS. Medium was removed, fresh medium contain-
ing 50 lCi}ml of [$&S]methionine}cysteine (ICN Biomedicals)
was added and the cells were metabolically labelled at 37 °C under
air}CO
#
(19:1) for 12 h. Supernatants were pre-cleared for 4 h
with Protein G–Sepharose at 4 °C. Specific immunoprecipitations
of the pre-cleared supernatants were performed in the presence
of mAb HC1}6 (anti-PECAM-1) or mAb 44G4 (anti-endoglin),
with Protein G–Sepharose. After incubation overnight at 4 °C,
immunoprecipitates were isolated by centrifugation, washed
twice with PBS at 4 °C and then subjected to SDS}PAGE [10%
(w}v) gel]. Detection of $&S-labelled proteins was revealed with a
PhosphorImager 410A and ImageQuant software (Molecular
Dynamics).
Cell surface biotinylation
Transiently transfected COS-7 cells were washed at 4 °C with





}10 mM HEPES (pH 7.4)] and left to equilibrate
for 30 min at 4 °C in the same buffer. Cells were washed again
and fresh Hepes buffer containing 0.5 mg}ml of sulpho-
succinimidyl 6-(biotinamido)hexanoate (NHS-LC-biotin ; Pierce
Chemicals, Rockville, IL, U.S.A.) was added. After incubation
at 4 °C for 2 h, the reaction was stopped by washing the cells
twice with Hepes buffer. Specific immunoprecipitations in the
presence of mAb CLE4 (anti-endoglin), mAb NIH31-2 [anti-
(PECAM-1)] or mAb HC1}6 were performed as described above.
Immune complexes were subjected to SDS}PAGE [7.5% (w}v)
gel] under non-reducing conditions, then electrotransferred to
nitrocellulose. Filters were blocked with 5% (w}v) milk powder
in PBS for 1 h and then incubated with 2 lg}ml of streptavidin
conjugated with horseradish peroxidase (Pierce Chemicals) for
2 h at room temperature. Biotinylated antigens were detected by
enhanced chemiluminescence.
Receptor affinity labelling
Affinity-labelling assays were basically performed as described
[29]. For cross-linking experiments, cells infected with vaccinia
virus recombinants were incubated in Hepes buffer containing
0.1% BSA with 50 pM "#&I-TGF-b1 (specific radioactivity
1200–2000 Ci}mmol; Amersham Ibe! rica, Madrid, Spain) for
4 h. Cells were washed and radiolabelled TGF-b1 was cross-
linked with 0.30 mM disuccinimidyl suberate (Pierce) in Hepes
buffer for 15 min at 4 °C. Cells were washed four times and
solubilized in lysis buffer. The total extracts were subjected to
specific immunoprecipitation. Immunoprecipitations were per-
formed with mAb 44G4 (anti-endoglin). Detection of the "#&I-
labelled receptors was revealed by standard autoradiography.
RNA preparation and Northern blot analysis
Total cellular RNA was isolated by using guanidinium thio-
cyanate}phenol}chloroform [30]. RNA samples (10 lg) were
denatured and then fractionated in 1.1% (w}v) agarose}
formaldehyde gels and blotted to nitrocellulose. Membranes
were hybridized in 50% (v}v) formamide at 65 °C with excess
$#P-labelled probes and washed under highly stringent conditions
(0.2‹SSC}0.5% SDS at 65 °C); radiolabelled bands were de-
tected with a PhosphorImager 410A and ImageQuant sofware
(Molecular Dynamics). The probe used was the 2.4 kb EcoRI
insert of endoglin in pcEXV-EndoS [14].
RESULTS
Expression analysis of transmembrane isoforms of endoglin by
using recombinant vaccinia virus
Vaccinia is a poxvirus with the capacity to infect a wide host
range in itro and in io of mammalian cell types, including
endothelial cells ; it can be used as an expression vector producing
relatively high levels of the corresponding recombinant protein
[30]. To validate this expression system, we performed infection
in itro and in io with recombinant vaccinia virus containing
both L-endoglin or S-endoglin isoforms (Figure 1). Infection of
monkey kidney cells in itro led to a high expression of re-
combinant endoglin at the cell surface, as demonstrated by flow
cytometry (Figure 1A) and Western blot (results not shown)
analyses. To assess the functional status of the virally encoded
endoglin, "#&I-TGF-b
"
binding experiments were performed (Fig-
ure 1B). On infection with VV-Endo-L or with VV-Endo-S
constructs, a specific radiolabelled band corresponding to L-
endoglin or S-endoglin respectively was immunoprecipitated,
together with minor bands corresponding to the putative TFG-
b receptors types I and II, indicating that both isoforms are
functionally active. In addition, infection of mice and rabbits
with VV-Endo-L or VV-Endo-S resulted in the expression in io
of recombinant endoglin as detected by the presence of anti-
endoglin antibodies in the sera of the infected animals (Figures
1C and 1D). The specificity of these antibodies was demonstrated
by flow cytometry (Figure 1C) and Western blot (Figure 1D)
analyses by using myoblast transfectants expressing endoglin.
These results demonstrate the expression in itro and in io of
the two transmembrane isoforms of endoglin by using vaccinia
virus as a vector.
Expression analysis of recombinant truncated forms of endoglin
Once we had validated the vaccinia virus as an expression vector
for the normal endoglin, we approached the expression of
truncated forms of endoglin. Figure 2(A) represents different
endoglin constructs generated that truncate the protein at exon
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Figure 1 Characterization of endoglin expression on infection in vitro or in vivo with recombinant vaccinia viruses
(A) Analysis by flow cytometry of the endoglin present at the cell surface. BSC40 cells were infected with virus recombinants VV-TK−, VV-Endo-L or VV-Endo-S and, 24 h after infection, were
analysed by indirect immunofluorescence. Cells were incubated with either mAb 44G4 [anti-endoglin (a- endoglin)] or mAb anti-HA [anti-(vaccinia haemagglutinin) ; a-HA] as a control for infection,
followed by incubation with FITC-labelled F(ab«)2 rabbit anti-mouse Ig. (B) Analysis of binding of
125I-TGF-b1 to recombinant endoglin. BSC40 cells were infected with vaccinia virus recombinants
(VV-Endo-L, VV-Endo-S or VV-TK−) and incubated in Hepes buffer containing 0.1% BSA with 50 pM 125I-TGF-b1, followed by chemical cross-linking with disuccinimidyl suberate. Cell extracts
were subjected to immunoprecipitation with mAb P4A4 (anti-endoglin), followed by SDS/PAGE analysis under non-reducing conditions. 125I-labelled receptors were detected by autoradiography.
Bands corresponding to endoglin, endoglin oligomers and the putative TGF-b receptors I and II are indicated. The positions of molecular mass markers are indicated (in kDa) at the left. (C) Analysis
by flow cytometry of sera from vaccinia-infected mice. Myoblast transfectants expressing L-endoglin were stained by indirect immunofluorescence with sera obtained from mice infected with VV-
Endo-L, VV-Endo-S or VV-TK−, followed by incubation with FITC-labelled F(ab«)2 rabbit anti-mouse Ig. (D) Western blot analysis of serum from a vaccinia-infected rabbit. Parental myoblasts (L6E9)
and myoblast transfectants expressing L-endoglin (L6E9-Endo-L) or S-endoglin (L6E9-Endo-S) were lysed and total extracts were transferred to nitrocellulose. Specific immunodetection was performed
by incubation with the serum BN of a rabbit infected with VV-Endo-L, followed by peroxidase-conjugated goat anti-rabbit Ig (‘BN ’ serves to identify the specific animal). Endoglin was detected
by using a chemiluminescence assay. The positions of molecular mass markers are indicated (in kDa) at the left.
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Figure 2 Expression of truncated forms of endoglin by transient transfections
(A) Schematic diagram of the endoglin gene, showing the locations of truncated forms of endoglin (indicated by arrows). Each exon is shown as a box with the corresponding exon number. Exons
2–12 encode the extracellular domain, exon 13 encodes the transmembrane (TM) domain and exon 14 the cytoplasmic (CYT0) domain. Only protein-encoded regions are shown. Cysteine residues
(C) are numbered according to their position in the endoglin sequence. (B) Northern blot analysis. COS-7 cells were transfected with mutant endoglin constructs (Endo-S, Endo*276, Endo*431,
Endo*437 and Endo*614) ; after 72 h, total cellular RNA species were isolated. RNA blots were stained with ethidium bromide to reveal the 28 S rRNA. RNA blots were hybridized with an endoglin
probe ; specific bands were detected by autoradiography. (C) Metabolic labelling. COS-7 cells were transiently transfected with mutant endoglin constructs (Endo*276, Endo*431, Endo*437 or
Endo*614) with the use of Lipofectin. Cells transfected with a soluble form of PECAM-1 (sr-PECAM-1) or mock-transfected (control) were used as positive or negative controls respectively. Transfected
cells were labelled metabolically with 50 lCi/ml [35S]methionine/cysteine. Supernatants were subjected to specific immunoprecipitations with anti-endoglin (Endo*276, Endo*431, Endo*437,
Endo*614 and control) or with anti-PECAM-1 (sr-PECAM-1) mAb. Immunoprecipitates were subjected to electrophoresis on a 10% (w/v) polyacrylamide gel under non-reducing conditions. Detection
of the of 35S-labelled proteins was revealed with a PhosphorImager 410A. The positions of molecular mass markers are indicated (in kDa) at the left.
6 (Endo*276), exon 9B (Endo*431 and Endo*437) or exon 13
(Endo*614). These cDNA endoglin constructs, inserted into an
expression vector, were used in the transient transfection of COS
cells ; specific transcripts of transduced cells were detected by
Northern blot analysis (Figure 2B). Constructs Endo-S,
Endo*431, Endo*276 and Endo*437 each revealed a specific
endoglin band with a size corresponding to the individual
constructs. By contrast, Endo*614 did not show any specific
transcript, suggesting the instability of its message. Next we
investigated the protein expression of these constructs by meta-
bolic labelling followed by immunoprecipitation analysis (Figure
2C). Under non-reducing conditions, polypeptides of approx.
130 and 120 kDa were immunoprecipitated from supernatants of
cells transfected with Endo*431 and Endo*437 constructs re-
spectively. In addition, the same samples electrophoretically
separated under reducing conditions yielded polypeptides of
approx. 66–70 kDa, which is in agreement with the predicted size
of the monomeric truncated forms of endoglin. As expected from
the Northern blot analysis, construct Endo*614 did not show a
specific band in cell lysates or supernatants ; neither did Endo*276
in spite of the presence of specific transcripts. As a control for the
experiment, a soluble form of PECAM-1 of approx. 100 kDa
was included. These experiments indicate that productive con-
structs Endo*431 and Endo*437 are able to yield stable mRNA
and protein products, whereas non-productive constructs
Endo*276 and Endo*614 are not.
Disulphide bonds in endoglin mutants
Immunoprecipitation analysis with Endo*431 (encoding residues
Met"–Ser%$") and Endo*437 (encoding residues Met"–Arg%$()
under reducing or non-reducing conditions (Figure 2C) indicated
that cysteine residues involved in disulphide dimerization are
located within the endoglin fragment Met"–Cys%"#. To analyse
further the participation of this region in the dimerization process,
a chimaeric construct encoding the leader sequence and the first
two IgG domains of PECAM-1 fused to residues Phe#)#–Ala’&)
of endoglin was made (Figure 3A). COS cells were transiently
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Figure 3 Expression of PECAM-1/endoglin chimaera
(A) Schematic representation of the predicted protein encoded by the pCEXV-PECAM-1/Endo plasmid. The N-terminal region contains the leader sequence (L) and IgG domains 1 and 2 of the
human PECAM-1 followed by residues Phe282–Ala658 of endoglin (encoded by part of exon 7 and exons 8–14). Abbreviations are as given in the legend to Figure 2. (B) Immunoprecipitation analysis.
COS cells were transiently transfected with the pCEXV-PECAM-1/Endo plasmid, biotinylated on their surface, lysed and immunoprecipitated with mAb CLE4 [anti-(fragment Gly331–Gly586 of endoglin)],
NIH31-2 [anti-(IgG domains 1–2 of PECAM-1)] or HC1/6 [anti-(IgG domains 3–6 of PECAM-1)]. Samples were separated by SDS/PAGE under either reducing (R) or non-reducing (NR) conditions
and electrotransferred to nitrocellulose membranes. Biotinylated proteins were detected with streptavidin conjugated to horseradish peroxidase by using a chemilumiscence assay. The positions
of the chimaeras are indicated by arrows. The positions of molecular mass markers are indicated (in kDa) at the left.
transfected with this construct and the recombinant protein was
characterized by biotinylation followed by immunoprecipitation
and SDS}PAGE analysis (Figure 3B). mAb CLE4 (anti-endoglin
fragment Gly$$"–Gly&)’) and mAb NIH31-2 [anti-(PECAM-1)
IgG domains 1–2], but not mAb HC1}6 [anti-(PECAM-1) IgG
domains 3–6] recognized a polypeptide of approx. 210 kDa
under non-reducing conditions. When separated under reducing
conditions, the recombinant protein yielded a monomer of
approx. 85 kDa, indicating that disulphide bonds are responsible
for the dimeric nature of the chimaera. In principle, the par-
ticipation of the PECAM-1 fragment in disulphide linkages can
be excluded because the complete PECAM-1 molecule is ex-
pressed as a single polypeptide [31]. Thus cysteine residues
contained within the endoglin fragment Phe#)#–Ala’&) are prob-
ably responsible for the disulphide dimerization. This fragment
and fragments Met"–Arg%$( and Met"–Ser%$", which yield dimeric
forms of endoglin, have in common six cysteine residues (Cys$$!,
Cys$&!, Cys$’$, Cys$)#, Cys$*% and Cys%"#), suggesting their in-
volvement in endoglin dimerization.
Recombinant vaccinia virus encoding truncated forms of endoglin
Constructs Endo*276 and Endo*431 were selected, as being
representative of non-productive and productive mutant alleles
respectively, for further studies with the vaccinia system. There-
fore recombinant vaccinia virus containing the truncated forms
Endo*276 and Endo*431 were generated. As depicted in Figure
4(A), infection of BSC-40 cells in itro with these recombinants,
followed by SDS}PAGE under non-reducing conditions and
Western blot analyses with antibodies against endoglin, allowed
the specific recognition of a soluble polypeptide of approx.
130 kDa, corresponding to the Endo*431 construct. In addition,
extracts from VV-Endo*431-infected cells separated electro-
phoretically under reducing conditions yielded a single poly-
peptide of approx. 66 kDa, indicating the dimeric nature of the
soluble protein. However, in the same experiment, no specific
polypeptide was detected with the Endo*276 construct. This lack
of recognition is apparently not due to the sole intracytoplasmic
retention of the recombinant protein, because immuno-
fluorescence staining of permeabilized cells infected with VV-
Endo*276 did not reveal any cytoplasmic localization of the
antigen (results not shown). Nevertheless intracytoplasmic re-
tention associated with a rapid degradation of the protein cannot
be excluded. Furthermore, the expression of the truncated
proteins in io was assayed by infecting mice with the re-
combinant virus VV-Endo*431 or VV-Endo*276 and the pres-
ence of antibodies to endoglin was tested for in the sera of the
infected animals (Figure 4B). Flow cytometry analysis with cell
transfectants expressing human endoglin demonstrated the pres-
ence of specific antibodies against endoglin in the sera of animals
infected with the recombinant Endo*431 but not in the sera of
animals infected with the Endo*276 construct. As a positive
control, a mAb against endoglin was included.
These experiments demonstrate that the truncated endoglin
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Figure 4 Characterization of vaccinia virus recombinants expressing
truncated forms of endoglin
(A) Western blot analysis. BSC-40 cells were infected with VV-Endo*276, VV-Endo*431 or VV-
TK− ; 12 h after infection, supernatants were collected and concentrated. The concentrates were
subjected to SDS/PAGE and samples were transferred to nitrocellulose. Specific immuno-
detection was performed by incubation with mouse anti-endoglin antibodies followed by
peroxidase-conjugated goat anti-mouse Ig. Soluble endoglin was detected by using a
chemiluminescence assay. The positions of molecular mass markers are indicated (in kDa) at
the left. (B) Flow cytometry analysis. Myoblast transfectants expressing L-endoglin (L6E9-Endo-
L) were stained by indirect immunofluorescence with sera of mice infected with VV-Endo*276
or VV-Endo*431, followed by incubation with FITC-labelled F(ab«)2 rabbit anti-mouse Ig. This
is a representative experiment with the use of one of six different mice sera per recombinant
virus. Sera from VV-TK−-infected mice yielded a negative staining similar to that of anti-VV-
Endo*276 (results not shown).
form Endo*431, but not Endo*276, can be expressed on infection
in itro and in io by using recombinant vaccinia virus.
Effect of soluble forms of endoglin on the expression of
transmembrane endoglin
As both mutant and normal endoglin alleles are present in HHT
patients, it was of interest to investigate whether the soluble
forms of endoglin had any effect on the expression of the normal
protein. First, we used myoblast transfectants expressing the L-
endoglin isoform as hosts for different recombinant vaccinia
viruses (Figure 5A). Flow cytometry analysis of control cells
demonstrated the relatively high expression of endoglin, which
was increased further on infection with a vaccinia virus encoding
the transmembrane endoglin. In contrast, infections with the
vaccinia virus expressing the truncated constructs Endo*431 or
Endo*276 did not affect the levels of expression of the normal
endoglin. Similarly, infection with a control TK− virus did not
alter endoglin expression in the transfectants. Next, we analysed
primary cultures of human endothelial cells, which might be
expected to be more representative of the physiological situation
(Figure 5B). Again, infection with VV-Endo*431, VV-Endo*276
or VV-TK− did not affect the endogenous expression of endoglin
by endothelial cells, as determined by flow cytometry. As a
control for the viral infection, a mAb specific for the vaccinia
haemagglutinin expressed at the cell surface of infected cells was
used.
Because endoglin is a disulphide-linked dimer, there is a
possibility of the formation of heterodimers between trans-
membrane and soluble endoglin forms at the cell surface. To test
this possibility, we used the mouse fibroblast cell line NCTC,
which expresses murine endoglin [7]. The existence of inter-
species dimers between human and murine transmembrane
endoglins could be demonstrated by using non-cross-reactive
mAb against murine or human endoglin (Figure 6A). Mouse
fibroblasts were infected with VV-Endo-L, lysed and immuno-
precipitated with anti-endoglin antibodies. Western blot analysis
of these samples revealed that the mAb MJ7}18 was able to
recognize the mouse endoglin co-immunoprecipitated by an anti-
(human endoglin) mAb. In contrast, no significant recognition
was obtained in a parallel experiment with uninfected fibroblasts.
As expected, mAb MJ7}18 clearly recognized the MJ7}18
immunoprecipitates from both infected and uninfected fibro-
blasts. Next, we analysed the possible formation of heterodimers
between truncated and soluble endoglin forms at the cell surface.
After infection with VV-Endo*431, VV-TK− or VV-Endo-L,
mouse fibroblasts were analysed by immunofluorescence flow
cytometry (Figure 6B). There was evidence of expression of the
endogenous endoglin in all cases by the specific staining with a
rat mAb against mouse endoglin. In contrast the reactivity of a
mAb to human endoglin showed the expression of the re-
combinant transmembrane protein in VV-Endo-L-infected cells
but the truncated form of endoglin could not be detected at the
cell surface in the case of VV-Endo*431. In this experiment the
VV-TK− construct was used as a negative control.
These results demonstrate that the expression of truncated
forms of endoglin does not affect the levels of expression of the
normal protein. In addition, the expression of a soluble form of
endoglin does not associate with the transmembrane form at the
cell surface.
DISCUSSION
Vaccinia virus is a powerful expression system that permits the
appropriate transport, secretion, processing and post-trans-
lational modifications dictated by the primary structure of the
recombinant protein and the cell type used as a host [32]. Here
we have used this system to express human endoglin in mam-
malian cells. After infection in itro with recombinant vaccinia
virus containing L-endoglin or S-endoglin, the transmembrane
antigen could be detected at the cell surface by flow cytometry
and Western blot analyses. Infection of mice and rabbits in io
with the same vaccinia constructs also allowed the expression of
recombinant endoglin as determined by the presence of endoglin-
specific antibodies in the sera of the infected animals. Fur-
thermore, the recombinant endoglin expressed by the infected
cells seems to be functional, as suggested by ligand binding
assays with radiolabelled TGF-b1. The conclusive results ob-
tained with the transmembrane forms of endoglin led us to
approach the expression of truncated forms of endoglin.
Many of the mutations found in HHT1, if translated, would
lead to truncated endoglin forms [2,19–23]. It was therefore of
interest to assess whether truncated forms of endoglin could be
expressed. Four different truncated constructs were initially
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Figure 5 Expression of truncated forms of endoglin on cells expressing normal endoglin
Transfectants L6E9-Endo-L (A) or human umbilical endothelial cells (B) expressing human endoglin were infected with VV-TK−, VV-Endo-L, VV-Endo*276 or VV-Endo*431 (m.o.i. 1), as indicated ;
18 h after infection, cells were stained by indirect immunofluorescence with either anti-endoglin (44G4 mAb ; a-endoglin) or anti-(vaccinia haemagglutinin) (a-HA) as a marker of infection, followed
by incubation with FITC-labelled F(ab«)2 rabbit anti-mouse Ig. Uninfected human umbilical endothelial cells or myoblasts (control) were included as negative controls. Cells were analysed by flow
cytometry as described in the Materials and methods section. Values of mean fluorescence intensity are indicated in the upper right corner of samples stained with anti-endoglin. The limits of
staining with an irrelevant antibody are indicated with a horizontal bar as a negative control (NC). Myoblast transfectants L6E9-Endo-L were positively stained with anti-(vaccinia haemagglutinin)
as a control for infection (results not shown).
transfected in COS cells. Northern blot analyses demonstrated
the absence of specific transcripts of Endo*614, containing a
stop codon immediately after the transmembrane region. This is
not surprising, considering that certain endoglin mutations in
HHT1 patients do not produce stable endoglin transcripts [22].
The lack of mutated transcripts probably reflects an early degra-
dation of mRNA encoding premature termination codons [33].
In contrast, Northern blot analyses demonstrated specific tran-
scripts of Endo*276, Endo*431 and Endo*437. However, only
Endo*431 and Endo*437 yielded a soluble protein in the
supernatant. The Endo*276 construct contains a stop codon at
the same location as an HHT1 mutant described previously [2].
The absence of a detectable protein encoded by Endo*276 is in
agreement with a recent report showing the inability of several
HHT1 mutations to be secreted [21], suggesting the intracellular
destination and degradation of the mutant protein, if translated.
Recently, Pichuantes et al. [34] have reported the expression of
different fragments of the extracellular domain of endoglin in
bacteria, where the synthesized protein was targeted to inclusion
bodies. However, to our knowledge, no soluble endoglin products
have yet been described in mammalian cells. Here we find that
both Endo*431 and Endo*437 constructs yielded secreted soluble
proteins as evidenced with the use of transient transfections and
recombinant vaccinia virus infections. This is the first report
describing the expression of a soluble form of endoglin in
mammalian cells. Given the negative results obtained with other
truncated constructs [21], it is unclear why only certain mutations
can be expressed at the protein level as soluble endoglin. It can
be speculated that thosemutations leading to a protein resembling
a situation in io are more likely to be expressed. In this regard,
it is of interest to note that the productive constructs Endo*431
and Endo*437 contain the stop codon close to or at a putative
protease cleavage site (RKK; position 437) similar to a betaglycan
sequence, postulated to be responsible for the generation of a
soluble form of betaglycan [35]. In support of the relevance of the
putative cleavage site of endoglin is the fact that it is located in
the border between sequences encoded by exon 9B and exon 10,
as well as the detection by ELISA of soluble endoglin complexes
in human sera [36]. The expression of recombinant soluble
endoglin might be useful in analysing the structure and function
of endoglin. Because endoglin is a disulphide-linked homodimer,
the soluble forms can help in elucidating the specific cysteine
residues involved in disulphide bridging. Therefore the fact that
constructs Endo*431 and Endo*437 and the PECAM-1}endoglin
chimaera can be expressed as dimers suggests that the common
endoglin fragment Cys$$!–Cys%"#, containing six cysteine residues,
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Figure 6 Inter-species dimerization between human and mouse endoglins
(A) Dimerization between human and mouse transmembrane endoglins. Uninfected or VV-Endo-
L-infected mouse fibroblasts were lysed and subjected to immunoprecipitation (IP) with mAb
P4A4 [anti-(human endoglin)], MJ7/18 [anti-(mouse endoglin)] or HC1/6 [anti-(PECAM-1)], as
indicated. Immunoprecipitates were subjected to SDS/PAGE under reducing conditions, then
transferred to nitrocellulose. Filters were incubated with the rat mAb MJ7/18 followed by
peroxidase-conjugated rabbit anti-rat Ig. The presence of mouse endoglin was revealed by using
a chemiluminescence assay. The mAb HC1/6 was used as a negative control. The positions
of molecular mass markers are indicated (in kDa) at the left. (B) Flow cytometry analysis of
mouse fibroblasts after infection with vaccinia virus recombinants expressing a truncated form
of human endoglin. Mouse fibroblasts NCTC929 expressing endogenous endoglin were infected
with with VV-TK−, VV-Endo-L or VV-Endo*431 as indicated. After 18 h, the three recombinant
viruses produced a similar cytopathic effect. Cells were then detached from the plates and
stained by indirect immunofluorescence with either anti-(mouse endoglin) (MJ7/18 mAb ; a-
murine endoglin) or anti-(human endoglin) (SN6h mAb ; a-human endoglin), followed by
incubation with FITC-labelled F(ab«)2 goat anti-rat Ig or rabbit anti-mouse Ig respectively. Cells
were analysed by flow cytometry as described in the Materials and methods section. Values
of mean fluorescence intensity are indicated in the upper right corner of samples stained with
anti-(human endoglin). The limits of staining with an irrelevant antibody are indicated with a
horizontal bar as a negative control (NC).
is involved in disulphide bond formation. More detailed studies
by site-directed mutagenesis are required to identify the specific
cysteine residues participating in endoglin dimerization.
Taken together, in the present study and previous reports
[21,22] three different types of behaviour of the truncated mutants
of endoglin are observed: (1) those that do not produce stable
transcripts ; (2) those that produce stable transcripts but do not
secrete the protein; and (3) those that secrete the protein. So far,
all the HHT1 mutations analysed at the protein and mRNA level
have belonged to the first two types, clearly supporting a
haploinsufficiency model of the disease. According to this model
the mutant allele is not secreted and therefore it is unable to help
or interfere in the function of the normal allele. This is in
agreement with the fact that infection with VV-Endo*276, which
encodes an HHT1 mutation, does not interfere with the ex-
pression of the normal allele. In the pathological situation, when
the level of the normal endoglin allele does not reach a minimal
threshold for its function, HHT1 is triggered. This haplo-
insufficiency model has been confirmed by the existence of null
allele mutations in certain HHT1 patients [23]. No secreted
protein has yet been reported in HHT1 patients. Nevertheless, to
mimic a possible situation in io, the effect of a soluble endoglin
on the expression of normal endoglin was addressed by using
recombinant vaccinia virus, which allows the infection of all the
cells in culture. On infection with VV-Endo*431 of endoglin-
expressing cells, no association of the soluble form with the
transmembrane endoglin could be detected; neither were sig-
nificant differences observed in the level of expression of the
transmembrane endoglin. In summary, these results suggest that
potential HHT1 mutations leading to the production of a soluble
form of endoglin would behave in accordance with a haplo-
insufficiency model. It will be of interest to analyse the possible
effects of the expression in io of soluble endoglin encoded by
the constructs reported here.
We thank Dr. Michelle Letarte for encouraging discussions, Dr. Peter Newman for
the PECAM-1 plasmid, Francisco Garcı!a Tabares for excellent technical assistance,
Manuel Moreno for help with infected animals, Mo! nica Fontenla and Victoria Mun4 oz
for photography, and Aurelio Hurtado for delineation. This work has been supported
by grants from Comisio! n Interministerial de Ciencia y Tecnologı!a (CICYT-SAF97-
0034 and CICYT-BIO94-0118), Comunidad Auto! noma de Madrid (CAM) and Biomed
Program of the European Community (BMH4-CT95-0995).
REFERENCES
1 Ferna! ndez-Ruiz, E., St-Jacques, S., Bello! n, T., Letarte, M. and Bernabe! u, C. (1993)
Cytogenet. Cell Genet. 64, 204–207
2 MacAllister, K. A., Grogg, K. M., Johnson, D. W., Gallione, C. J., Baldwin, M. A.,
Jackson, C. E., Helmbold, E. A., Markel, D. S., McKinnon, W. C., Murrell, J. et al.
(1994) Nat Genet. 8, 345–351
3 Guttmacher, A. E., Marchuk, D. A. and White, R. I. (1995) New Engl. J. Med. 333,
918–924
4 Shovlin, C. L. (1997) Thromb. Haemost. 78, 145–150
5 Gougos, A. and Letarte, M. (1988) J. Immunol. 141, 1925–1933
6 Gougos, A., St. Jacques, S., Greaves, A., O’Connell, P. J., d’Apice, A. J. F., Bu$ hring,
H. J., Bernabe! u, C., van Mourik, J. A. and Letarte, M. (1992) Int. Immunol. 4, 83–92
7 St-Jacques, S., Cymerman, U., Pece, N. and Letarte, M. (1994) Endocrinology
(Baltimore) 134, 2645–2657
8 Robledo, M. M., Hidalgo, A., Lastres, P., Arroyo, A. G., Bernabe! u, C., Sa! nchez-Madrid,
F. and Teixido! , J. (1996) Br. J. Haematol. 93, 507–514
9 Lastres, P., Bello! n, T., Caban4 as, C., Sa! nchez-Madrid, F., Acevedo, A., Gougos, A.,
Letarte, M. and Bernabe! u, C. (1992) Eur. J. Immunol. 22, 393–397
10 Rokhlin, O. W., Cohen, M. B., Kubagawa, H., Letarte, M. and Cooper, M. D. (1995)
J. Immunol. 154, 4456–4465
11 Zhang, H., Shaw, A. R. E., Mak, A. and Letarte, M. (1996) J. Immunol. 156,
565–573
12 Haruta, Y. and Seon, B. K. (1986) Proc. Natl. Acad. Sci. U.S.A. 83, 7898–7902
13 Gougos, A. and Letarte, M. (1990) J. Biol. Chem. 265, 8361–8364
14 Bello! n, T., Corbı!, A., Lastres, P., Cale! s, C., Cebria! n, M., Vera, S., Cheifetz, S.,
Massague! , J., Letarte, M. and Bernabe! u, C. (1993) Eur. J. Immunol. 23, 2340–2345
15 Cheifetz, S., Bello! n, T., Cale! s, C., Vera, S., Bernabe! u, C., Massague! , J. and Letarte,
M. (1992) J. Biol. Chem. 267, 19027–19030
16 Yamashita, H., Ichijo, H., Grimsby, S., More! n, A., ten Dijke, P. and Miyazono, K.
(1994) J. Biol. Chem. 269, 1995–2001
17 Lastres, P., Letamendı!a, A., Zhang, H., Rius, C., Almendro, N., Raab, U., Lo! pez, L. A.,
Langa, C., Fabra, A., Letarte, M. and Bernabe! u, C. (1996) J. Cell Biol. 133,
1109–1121
18 Johnson, D. W., Berg, J. N., Baldwin, M. A., Gallione, C. J., Marondel, I., Yoon, S.-J.,
Stenzel, T. T., Speer, M., Pericak-Vance, M. A., Diamond, A. et al. (1997) Nat. Genet.
13, 189–195
19 MacAllister, K. A., Baldwin, M. A., Thukkani, A. K., Gallione, C. J., Berg, J. N.,
Porteous, M. E., Guttmacher, A. E. and Marchuk, D. A. (1995) Hum. Mol. Genet. 4,
1983–1985
20 Yamaguchi, H., Azuma, H., Shigekiyo, T., Inoue, H. and Saito, S. (1997) Thromb.
Haemost. 77, 243–247
21 Pece, N., Vera, S., Cymerman, U., White, R. I., Wrana, J. L. and Letarte, M. (1997)
J. Clin. Invest. 100, 2568–2579
22 Shovlin, C. L., Hughes, J. M., Scott, J., Seidman, C. E. and Seidman, J. G. (1997)
Am. J. Hum. Genet. 61, 68–79
# 1999 Biochemical Society
588 U. Raab and others
23 Gallione, C. J., Klaus, D. J., Yeh, E. Y., Stenzel, T. T., Xue, Y., Anthony, K. B.,
McAllister, K. A., Baldwin, M. A., Berg, J. N., Lux, A. et al. (1998) Hum. Mutat. 11,
286–294
24 Caban4 as, C., Sa! nchez-Madrid, F., Bello! n, T., Figdor, C. G., Te Velde, A. A., Ferna! ndez,
J. M., Acevedo, A. and Bernabe! u, C. (1989) Eur. J. Immunol. 19, 1373–1378
25 Letarte, M., Bourdeau, A., Vera, S., Pece, N., Greaves, A., Dignat-George, F., Mutin,
M., Kraling, B., Linask, K., O’Brien, E. et al. (1997) in Leucocyte Typing VI
(Kishimoto, T., Kikutani, H., von dem Borne, A. E. G.Kr., Goyert, S. M., Mason, D. Y.,
Miyasaka, M., Moretta, L., Okumura, K., Shaw, S., Springer, T. A. et al., eds.), pp.
703–708, Garland Publishing, New York
26 Yan, H.-C., Newman, P. J. and Albelda, S. M. (1995) in Leucocyte Typing V
(Schlossman, S. F., Boumsell, L., Gilks, W., Harlan, J. M., Kishimoto, T., Morimoto,
C., Ritz, J., Shaw, S., Silverstein, R., Springer, T. et al., eds.), pp. 1261–1262, Oxford
University Press
Received 10 August 1998/20 January 1999 ; accepted 10 February 1999
27 Gee, A. Z. and Butcher, E. C. (1994) Gene 138, 201–206
28 Lo! pez-Guerrero, J. A., Lo! pez-Bote, J. P., Ortiz, M. A., Gupta, R. S., Pa! ez, E. and
Bernabe! u, C. (1993) Infect. Immun. 61, 4225–4231
29 Massague! , J. (1987) Methods Enzymol. 146, 174–195
30 Chomczynski, P. and Sacchi, N. (1987) Anal. Biochem. 162, 156–159
31 Newman, P. J. (1997) J. Clin. Invest. 100 (Suppl. 11), S25–S29
32 Moss, B. and Flexner, C. (1987) Annu. Rev. Immunol. 5, 305–324
33 Maquat, L. E. (1995) RNA 1, 453–465
34 Pichuantes, S., Vera, S., Bourdeau, A., Pece, N., Kumar, S., Wayner, E. A. and
Letarte, M. (1997) Tissue Antigens 50, 265–276
35 Lo! pez-Casillas, F., Cheifetz, S., Doody, J., Andre! s, J. L., Lane, W. S. and Massague! ,
J. (1991) Cell 67, 785–795
36 Blann, A. D., Wang, J. M., Wilson, P. B. and Kumar, S. (1996) Atherosclerosis 120,
221–226
# 1999 Biochemical Society
